Effect of 3'azido-2',3'-deoxythymidine (AZT) on experimental feline immunodeficiency virus infection in domestic cats.
The compound 3'azido-2',3'-deoxythymidine (AZT) inhibits the replication of feline immunodeficiency virus (FIV) in cell culture, and treatment with the compound has been reported to induce some clinical improvement in some cases of feline FIV infection. In order to determine the effect of prophylactic treatment with AZT on experimental FIV infection, cats were treated with the compound at 0.2, 1.0, 5, 25 or 50 mg kg-1 day-1 for 29 days. One day after the treatment was started, they were inoculated with 150 cat infectious doses of FIV. All the cats became viraemic, seroconverted and developed lymphadenopathy, although the onset of each was delayed in the cats given higher doses of AZT. Anaemia developed in the cats given high doses of AZT. Virus re-isolated from the cats given 50 mg kg-1 day-1 was as susceptible to AZT in cell culture as the inoculated virus. Thus AZT is much less effective in cats than might have been expected from the results of in vitro studies.
Smyth
N R
NR
Department of Veterinary Clinical Science, University of Liverpool.
Bennett
M
M
Gaskell
R M
RM
McCracken
C M
CM
Hart
C A
CA
Howe
J L
JL
D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D002415:Cats; D004797:Enzyme-Linked Immunosorbent Assay; D016181:Feline Acquired Immunodeficiency Syndrome / Q000097:blood / Q000188:drug therapy* / Q000276:immunology; D016089:Immunodeficiency Virus, Feline / Q000187:drug effects* / Q000302:isolation & purification; D008213:Lymphocyte Activation; D011897:Random Allocation; D013997:Time Factors; D015215:Zidovudine / Q000494:pharmacology / Q000627:therapeutic use*
D000914:Antibodies, Viral; D015215:Zidovudine